Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced participation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET.

Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced participation at the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. The live presentation will be available via webcast on the company's website.

Milestone focuses on innovative cardiovascular medicines, with its lead product candidate, etripamil, having recently completed a Phase 3 clinical program for treating paroxysmal supraventricular tachycardia (PSVT). It is also in a Phase 2 trial for atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates in both Canada and the United States.

Argus Session date unavailable

-4.43% session move Open Argus

Details

News Market Reaction – MIST

The recorded move for MIST in the trading session of this news was -4.43%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MONTREAL and CHARLOTTE, N.C., April 12, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will present at the 22^nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023 at 3:45 p.m. ET.

A live webcast of the presentation can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the presentation will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil recently completed its Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and is in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact:

David Pitts
Argot Partners
milestone@argotpartners.com
212-600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-22nd-annual-needham-virtual-healthcare-conference-301794837.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Milestone Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

Milestone Pharmaceuticals will present on April 19, 2023, at 3:45 p.m. ET.

How can I access the Milestone Pharmaceuticals conference presentation?

The conference presentation will be available via a live webcast on Milestone's website.

What is the focus of Milestone Pharmaceuticals?

Milestone Pharmaceuticals focuses on developing and commercializing innovative cardiovascular medicines.

What is etripamil and its current status?

Etripamil is Milestone's lead product candidate that recently completed a Phase 3 clinical trial for PSVT and is in a Phase 2 trial for AFib-RVR.

Where does Milestone Pharmaceuticals operate?

Milestone Pharmaceuticals operates in Canada and the United States.